• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Sandoz acquires inhaler developer Coalesce Product Development

Declaring that it is “determined to grow its portfolio in the complex generics space,” Novartis generics division Sandoz announced its acquisition of device device developer Coalesce Product Development. Coalesce’s inhaler technology include MDI, breath-actuated MDI, and DPI platforms. Sandoz said that it “sees respiratory as a key pillar of its ambitious long-term growth strategy and intends to actively explore further opportunities both in-house and externally.”

Sandoz’s current respiratory products include the AirFluSal Forspiro fluticasone propionate / salmeterol DPI, which is approved in Europe as well as in Mexico and South Korea. In January 2020, Sandoz discontinued development of its generic fluticasone propionate / salmeterol DPI for the US market. The company acquired distribution rights to an authorized generic of Proventil HFA albuterol MDI from Kindeva Drug Delivery in March 2021, and in June 2021, the FDA approved the company’s ANDA for its generic albuterol MDI. Sandoz also launched an authorized generic of Emergent BioSolution’s Narcan nasal spray in December 2021. 

Sandoz CEO Richard Saynor commented, “Respiratory and complex generics are areas of relatively high unmet medical need, due largely to their comparatively high technical complexity. At Sandoz, we have the experience and expertise to succeed in these fields and this acquisition offers us a significant new growth platform, particularly in the US and Europe, reinforcing our commitment to pioneer access for patients.”

Read the Sandoz press release.

Share

published on March 14, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews